SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

N/ANot Yet RecruitingNCT07272057

Shanghai Chest Hospital200 enrolled

Overview

The goal of this clinical trial The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are: * Does adding an SGLT2 inhibitor to standard cancer treatment improve survival? * Does it cause more or fewer cardiovascular toxicity? * What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works. Participants will: * Be adults diagnosed with advanced lung cancer and type 2 diabetes. * Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment. * Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Lung Cancer

Interventions

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Lung cancer patients receiving standard anti-tumor treatment; type 2 diabetes; patients with a score of 0-2 assessed by Eastern Cooperative Oncology Group's performance status; the patients agreed to participate in this study. Exclusion Criteria: * Severe abnormalities in liver, kidney or heart functions; expected lifespan less than 3 months.

Outcomes

Primary Outcomes

Number of Participants with death

Time frame: From enrollment to the end of treatment at 12 months

Secondary Outcomes

Number of Participants with new-onset atrial fibrillation/flutter, acute coronary syndrome, myocarditis, massive pericardial effusion, heart failure and third-degree atrioventricular block.